These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


97 related items for PubMed ID: 16621418

  • 1. Physicochemical characterization of meloxicam-mannitol binary systems.
    Nassab PR, Rajkó R, Szabó-Révész P.
    J Pharm Biomed Anal; 2006 Jun 16; 41(4):1191-7. PubMed ID: 16621418
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo investigations on the binary meloxicam-mannitol system.
    Nassab PR, Blazsó G, Nyári T, Falkay G, Szabó-Révész P.
    Pharmazie; 2008 Apr 16; 63(4):319-20. PubMed ID: 18468395
    [Abstract] [Full Text] [Related]

  • 3. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems.
    Naidu NB, Chowdary KP, Murthy KV, Satyanarayana V, Hayman AR, Becket G.
    J Pharm Biomed Anal; 2004 Apr 01; 35(1):75-86. PubMed ID: 15030882
    [Abstract] [Full Text] [Related]

  • 4. Analysis of co-spray-dried meloxicam-mannitol systems containing crystalline microcomposites.
    Pomázi A, Ambrus R, Sipos P, Szabó-Révész P.
    J Pharm Biomed Anal; 2011 Sep 10; 56(2):183-90. PubMed ID: 21652159
    [Abstract] [Full Text] [Related]

  • 5. Self-modeling curve resolution method applied for the evaluation of dissolution testing data: a case study of meloxicam-mannitol binary systems.
    Rajkó R, Nassab PR, Szabó-Révész P.
    Talanta; 2009 Jul 15; 79(2):268-74. PubMed ID: 19559876
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Preparation of a solid dispersion by a dropping method to improve the rate of dissolution of meloxicam.
    Bashiri-Shahroodi A, Nassab PR, Szabó-Révész P, Rajkó R.
    Drug Dev Ind Pharm; 2008 Jul 15; 34(7):781-8. PubMed ID: 18612916
    [Abstract] [Full Text] [Related]

  • 8. Utilization of spray drying technique for improvement of dissolution and anti-inflammatory effect of Meloxicam.
    Shazly G, Badran M, Zoheir K, Alomrani A.
    Pak J Pharm Sci; 2015 Jan 15; 28(1):103-11. PubMed ID: 25553688
    [Abstract] [Full Text] [Related]

  • 9. Solid-state characterization and dissolution properties of meloxicam-moringa coagulant-PVP ternary solid dispersions.
    Noolkar SB, Jadhav NR, Bhende SA, Killedar SG.
    AAPS PharmSciTech; 2013 Jun 15; 14(2):569-77. PubMed ID: 23483432
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone K-30.
    El-Badry M, Fathy M.
    Drug Dev Ind Pharm; 2006 Feb 15; 32(2):141-50. PubMed ID: 16537195
    [Abstract] [Full Text] [Related]

  • 11. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam.
    Ambrus R, Kocbek P, Kristl J, Sibanc R, Rajkó R, Szabó-Révész P.
    Int J Pharm; 2009 Nov 03; 381(2):153-9. PubMed ID: 19616609
    [Abstract] [Full Text] [Related]

  • 12. Analysis of polymorphic contamination in meloxicam raw materials and its effects on the physicochemical quality of drug product.
    Jacon Freitas JT, Santos Viana OMM, Bonfilio R, Doriguetto AC, de Araújo MB.
    Eur J Pharm Sci; 2017 Nov 15; 109():347-358. PubMed ID: 28844846
    [Abstract] [Full Text] [Related]

  • 13. Characterization of ternary complexes of meloxicam-HPbetaCD and PVP or L-arginine prepared by the spray-drying technique.
    El-Maradny HA, Mortada SA, Kamel OA, Hikal AH.
    Acta Pharm; 2008 Dec 15; 58(4):455-66. PubMed ID: 19103579
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
    Agarwal V, Alayoubi A, Siddiqui A, Nazzal S.
    Drug Dev Ind Pharm; 2013 Nov 15; 39(11):1681-9. PubMed ID: 23072611
    [Abstract] [Full Text] [Related]

  • 17. Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies.
    Shende PK, Gaud RS, Bakal R, Patil D.
    Colloids Surf B Biointerfaces; 2015 Dec 01; 136():105-10. PubMed ID: 26364091
    [Abstract] [Full Text] [Related]

  • 18. Kneading technique for preparation of binary solid dispersion of meloxicam with poloxamer 188.
    Ghareeb MM, Abdulrasool AA, Hussein AA, Noordin MI.
    AAPS PharmSciTech; 2009 Dec 01; 10(4):1206-15. PubMed ID: 19862626
    [Abstract] [Full Text] [Related]

  • 19. Solid dispersion of meloxicam: factorially designed dosage form for geriatric population.
    Pathak D, Dahiya S, Pathak K.
    Acta Pharm; 2008 Mar 01; 58(1):99-110. PubMed ID: 18337211
    [Abstract] [Full Text] [Related]

  • 20. Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.
    Alladi S, Shastri NR.
    Arch Pharm Res; 2015 Mar 01; 38(5):801-12. PubMed ID: 24752862
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 5.